What Caught Our Attention in the Investment World? – Week of August 30-September 3, 2021

By Kuldip K. Ambastha

On Friday, September 3, 2021, the stock of Forte Biosciences, Inc. (FBRX) stood out for its substantial trading day loss of -82.3%. Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on potential treatments for inflammatory skin diseases. The company released results of a Phase 2 clinical trial of FB-401, related to the treatment of atopic dermatitis. The results did not show statistical significance in terms of a meaningful decrease (specifically, 50% or better) in atopic dermatitis disease severity in clinical trial patients who were given FB-401. The results were made public on Thursday, September 2, 2021 and led to a -4.4% loss for that trading day. On the next trading day, the more significant -82.3% loss was seen due to the clinical trial results combined with the announcement that various law firms are investigating potential securities fraud, unlawful business practices, and other federal securities law violations which may have happened at Forte Biosciences, Inc.

Keywords – Forte Biosciences, Inc., Forte Biosciences, Forte, biopharmaceutical, inflammatory skin disease, atopic dermatitis, FB-401, Phase 2, clinical trial, law.

Disclosure – The principals and clients of Ambastha Financial LLC have no positions in FBRX.

Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2021 – Ambastha Financial LLC.

Leave a Reply

Your email address will not be published. Required fields are marked *